...
首页> 外文期刊>Journal of hypertension >Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat
【24h】

Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat

机译:双血管紧张素1受体/内胚素抑制与血管紧张素型1受体抑制对脑卒中术中靶器官损伤的影响

获取原文
获取原文并翻译 | 示例

摘要

Objectives:The combination of AT1 blocker/neutroendopeptidase neprilysin inhibition (ARNi) represents an interesting approach to reduce cardiovascular risk in hypertension. We assessed the efficacy of ARNi, compared with angiotensin II type 1 receptor blockade alone, on blood pressure (BP) and on protection from target organ damage development in the stroke-prone spontaneously hypertensive rat (SHRSP).Methods:In high-salt fed SHRSP, we assessed plasma and tissue natriuretic peptides, urinary volume, BP and body weight over a short-term treatment (6 weeks) with either ARNi (sacubitril/valsartan 68mg/kg per day) or valsartan (30mg/kg per day), protection from stroke and renal damage (as documented by proteinuria) over 4 months of treatment with either sacubitril/valsartan or valsartan; the ability of either treatment to reduce progression of cerebrovascular and renal damage after 2 weeks of high-salt diet.Results:Higher levels of plasma and tissue atrial natriuretic peptide, of urinary cyclic guanosine 35monophosphate and urine volumes, along with lower BP levels, were found upon sacubitril/valsartan as compared with valsartan over the short-term treatment. Sacubitril/valsartan caused a significant reduction of both BP and proteinuria levels and complete prevention of stroke over the long-term treatment. Once organ damage was established, a significant delay of its progression was observed with sacubitril/valsartan.Conclusion:The dual angiotensin II type 1 receptor/neutroendopeptidase inhibition significantly increased atrial natriuretic peptide level and reduced BP. Complete prevention of stroke was achieved in this model. The ability of sacubitril/valsartan to reduce organ damage progression was superior to that of valsartan alone. ARNi may represent a highly effective therapeutic agent to protect from target organ damage development in hypertension.
机译:目的:AT1阻断/脱恶肽酶内胚素抑制(ARNI)的组合代表了降低高血压心血管风险的有趣方法。我们评估了Arni的功效,与血管紧张素II型1受体阻滞单独,在血压(BP)和脑卒中易于自发性高血压大鼠(SHRSP)中的靶器官损伤发育的保护中。方法:在高盐喂养中SHRSP,我们评估了血浆和组织利钠肽,尿体积,BP和体重在短期治疗(6周)与Arni(Sacubitril / Valsartan 68mg / kg /天)或缬沙坦(每天30mg / kg),保护中风和肾脏损伤(按蛋白尿记录)与骶盐/缬沙坦或缬沙坦治疗超过4个月;在高盐饮食后2周后,治疗减少脑血管血管和肾损伤进展的能力在短期治疗中与缬沙坦相比,在萨巴硝基/缬沙坦发现。 Sacubitril / Valsartan对BP和蛋白尿水平显着降低,并在长期治疗中完全预防中风。一旦建立了器官损伤,用骶骨/缬沙坦的遗传算法观察到其进展的显着延迟。结论:双血管紧张素II型1受体/脱肽酶抑制显着增加的心房利钠肽水平和降低的BP。在该模型中实现了完全预防行程。 Sacubitril / Valsartan减少器官损伤进展的能力优于单独的Valsartan。 Arni可以代表一种高效的治疗剂,以保护高血压中的靶器官损伤发育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号